Author Archives: Paul Cole

Regeneron v. Kymab – “Sufficiency” and Enablement in the U.K.

Guest post from Paul Cole. Regeneron Pharmaceuticals Inc v Kymab Ltd. [2020] UKSC 27 related to infringement of EP-B-1,360,287 and its divisional EP-B-2264123. The 287 parent related to a method of modifying an endogenous immunoglobulin variable region gene locus in … Continue reading

Posted in EP and UK Practice | Tagged | Leave a comment